Passive Immune-oncology Therapy (Antibody Drug Conjugate)
OBI-999, uses Globo H antibody to recognize the cancer cells with high Globo H expression and releases the active drug to prevent tumor growth and kill tumor cells. There is an ongoing effort in developing its patent portfolio; patent right has been granted in South Africa and the United States. OBI-999 was granted Orphan Drug Designation (ODD) for its use in gastric cancer in January 2020. Prior to that, it was also granted ODD for pancreatic cancer.
OBI-999, is currently at Phase I, Dose-Escalation for continuous evaluation on the dose limiting toxicity at the University of Texas MD Anderson Cancer Center in the United States. In 2020, OBI published an abstract at the American Society of Clinical Oncology (ASCO) virtual annual meeting, presenting the OBI-999 Phase I/II clinical trial process and preliminary data.